Parathyroid tissue in normocalcemic and hypercalcemic primary hyperparathyroidism recruited by health screening.
Parathyroid tissue from 57 women (mean age 65.5 years) with sporadic primary hyperparathyroidism (HPT) was analyzed mainly to clarify its characteristics versus tissue from those with normocalcemia. Patients were recruited by population-based health screening of menopausal women. Analysis of three or four total serum calcium values showed normocalcemia in 16 patients (mean 2.53 mmol/L); 20 and 21 of the women were consistently (mean 2.82 mmol/L) or intermittently (mean 2.59 mmol/L) hypercalcemic, respectively. Parathyroid operation demonstrated a single adenoma in 81% of the individuals, and these lesions were most prevalent and commonly dominated by oxyphil parathyroid cells in the persistently hypercalcemic patients. Chief cell hyperplasia (two or three abnormal glands) of the nodular type was found more often in the normocalcemic patients. Total glandular weight was the smallest (mean 270 mg) among the normocalcemic women and contributed to delicate decisions with regard to the extent of resection. Immunostaining of cryosections with a monoclonal antibody recognizing a putative Ca2+ sensor demonstrated variably heterogeneous down-regulation of the recognized glycoprotein in the pathologic parathyroid glands from all the individuals. Dose-response relations for PTH release and the cytoplasmic Ca2+ concentration ([Ca2+]i) were determined in Ca2+ 0.5-3.0 mmol/L by examining dispersed cells with radioimmunoassay and microfluorometry after fura-2 loading, respectively. ED50 for PTH release and [Ca2+]i and the [Ca2+]i concentrations at Ca2+ 3.0 mmol/L were the least deranged in cells from pathologic glands of the normocalcemic patients. The findings substantiate that the abnormal parathyroid tissue of normocalcemic HPT principally is characterized by the same, albeit less extensive, morphologic and functional derangements, which consistently have been demonstrated in patients with HPT accompanied by hypercalcemia and detected clinically.
Lundgren
E
E
Department of Surgery, University Hospital, S-751 85 Uppsala, Sweden.
Ridefelt
P
P
Akerström
G
G
Ljunghall
S
S
Rastad
J
J
D000236:Adenoma / Q000473:pathology; D000368:Aged; D000911:Antibodies, Monoclonal; D002118:Calcium / Q000097:blood* / Q000378:metabolism; D002614:Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology; D004396:Coloring Agents; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D005260:Female; D016257:Fura-2 / Q000008:administration & dosage / Q000494:pharmacology; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D006934:Hypercalcemia / Q000378:metabolism / Q000473:pathology*; D006961:Hyperparathyroidism / Q000378:metabolism / Q000473:pathology*; D006965:Hyperplasia; D008403:Mass Screening; D008593:Menopause; D009929:Organ Size; D010280:Parathyroid Glands / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D010281:Parathyroid Hormone / Q000378:metabolism; D010282:Parathyroid Neoplasms / Q000473:pathology; D016105:Parathyroidectomy
D000911:Antibodies, Monoclonal; D002614:Chelating Agents; D004396:Coloring Agents; D006023:Glycoproteins; D010281:Parathyroid Hormone; D002118:Calcium; D016257:Fura-2